EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance

Alessia Zinzi, Mario Gaio, Rosanna Ruggiero, Annamaria Mascolo, Maria Antonietta Riemma, Mattia Cipriani, Ludovica Vittoria Laino, Liberato Berrino, Francesco Rossi, Annalisa Capuano

Frontiers in Pharmacology · 29.04.2026 · 17

DOI: 10.3389/fphar.2026.1805842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Alessia Zinzi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The spread of counterfeit drugs represents a serious threat to public health because they may be ineffective or cause the onset of severe suspected adverse drug reactions (ADRs). To date, the traceability of semaglutide-based products, widely used off-label for weight loss, is not a well-studied area.

Methods

The aim of this study was to perform a descriptive analysis to explore and describe the characteristics of safety cases related to potential counterfeit semaglutide products by using the European pharmacovigilance database EudraVigilance. Individual Case Safety Reports (ICSRs) were retrieved over the period from 1 January 2018 to 31 December 2025.

Results

A total of 234 Individual Case Safety Reports (ICSRs) related to potential counterfeit semaglutide were retrieved from EudraVigilance, of which N = 172 (73.5%) were related to females and N = 83 (35.5%) to adult patients. A total of 89.3% of all suspected ADRs were serious. The most frequently reported suspected ADRs were “vomiting”, “nausea”, and “hypoglycemia”. The analysis of disproportionality showed a higher reporting frequency of “hypoglycemia”, “product use in unapproved indication”, “malaise”, and “drug ineffective” with potential counterfeit semaglutide compared to non-counterfeit semaglutide.

Discussion

The present pharmacovigilance study showed a useful role in identifying potential counterfeit medicine suspected ADRs. Further studies are warranted.

Schlagwörter

Stichwörter der Autor:innen

GLP-1counterfeit semaglutidecounterfeitingeudravigilanceobesitypharmacovigilancesafety

Autor:innen und Institutionen

  • Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
  • Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Naples, Italy.
  • Department of Experimental Medicine - Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Naples, Italy.

Zitieren

APA

Zinzi, A., Gaio, M., Ruggiero, R., Mascolo, A., Riemma, M. A., Cipriani, M., Laino, L. V., Berrino, L., Rossi, F., & Capuano, A. (2026). Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1805842

Vancouver

Zinzi A, Gaio M, Ruggiero R, Mascolo A, Riemma MA, Cipriani M, et al. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1805842

BibTeX
@article{Zinzi2026,
  author = {Zinzi, Alessia and Gaio, Mario and Ruggiero, Rosanna and Mascolo, Annamaria and Riemma, Maria Antonietta and Cipriani, Mattia and Laino, Ludovica Vittoria and Berrino, Liberato and Rossi, Francesco and Capuano, Annalisa},
  title = {Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1805842}
}
Kostenlos starten →